Figure S2 from Results of an Open-label, Phase 1a/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced or Metastatic Soft Tissue Sarcoma | Synapse
September 16, 2024
Figure S2 from Results of an Open-label, Phase 1a/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced or Metastatic Soft Tissue Sarcoma
Key Points
Key points are not available for this paper at this time.
Abstract
Figure S2: Waterfall plot for percent change in tumor size in cohort 1, cohort 2, and the dose-expansion cohort.